Study guide

6.2 Investigational Product Receipt, Dispensing, and Accountability

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

6.2 Investigational Product Receipt, Dispensing, and Accountability

Key Takeaways Explain This Topic AI

IP receipt involves verifying shipment conditions, confirming quantities, updating inventory logs, and acknowledging receipt in the IRT system.

Dispensing IP requires strict adherence to the protocol, including calculating correct dosages, double-checking kit numbers, and providing clear patient instructions.

Meticulous accountability records, including Master IP Logs and Subject-Specific IP Logs, must track every unit of IP from receipt at the site to final disposition.

Any discrepancies in IP accountability must be documented, investigated, and explained to ensure the integrity of the clinical trial data.

Last updated: October 2026

Investigational Product Receipt

The chain of custody for an investigational product begins the moment it arrives at the clinical site. A robust receipt process ensures that the site only accepts IP that is safe, intact, and properly documented.

The Receipt Process

When a shipment of IP arrives, the designated site staff must immediately perform the following steps:

Verify the Shipment: Check the physical package for signs of damage or tampering. Verify that the shipment is intended for your site and specific protocol.

Check the Temperature Monitor: Most IP shipments include a temperature monitor (e.g., a TempTale). The coordinator must stop the monitor, download the data, and verify that the IP remained within the acceptable temperature range during transit. If an excursion occurred, the IP must be quarantined immediately.

Inventory the Contents: Unpack the IP and match the physical contents (kit numbers, lot numbers, quantities) against the packing slip. Any discrepancies (e.g., missing kits, extra kits, mismatched numbers) must be noted.

Acknowledge Receipt: If the shipment is intact and correct, the coordinator must acknowledge receipt in the Interactive Response Technology (IRT) system or sponsor portal. This updates the site's digital inventory.

Update Site Logs: The receipt must be recorded on the Master IP Accountability Log, adding the new stock to the site's active inventory.

Store Immediately: Transfer the IP to the appropriate temperature-controlled, secure storage area without delay.

Real-World Example: A site receives a cooler containing a biologic requiring 2-8°C storage. The coordinator immediately stops the TempTale, downloads the PDF report, and confirms the temperature never exceeded 6°C. They verify the 10 vials match the packing slip, log into the IRT system to mark the 10 specific vial numbers as 'Received', sign the packing slip, and place the vials in the locked, monitored refrigerator. The signed packing slip and temperature report are filed in the pharmacy binder.

Dispensing Investigational Product

Dispensing IP to a subject is a high-risk activity. Errors in dispensing can lead to subjects receiving the wrong dose, the wrong drug, or an expired product, directly impacting their safety and the trial's validity.

The Dispensing Workflow

Verify Eligibility and Randomization: Before dispensing, confirm the subject has met all inclusion/exclusion criteria, has signed the current informed consent, and has been randomized or assigned treatment in the IRT system.

Obtain the Assignment: The IRT system will assign specific IP kit numbers for the subject. The coordinator must print or document this assignment.

Retrieve the IP: Go to the storage area and retrieve only the specific kit numbers assigned by the system.

Verify Expiration/Retest Date: Check the label or the IRT system to ensure the IP will not expire before the subject finishes the course of treatment.

Double-Check: A best practice (and often a protocol requirement) is to have a second qualified staff member verify that the retrieved kit matches the IRT assignment exactly.

Prepare the IP (if applicable): Some protocols require the IP to be reconstituted or drawn into syringes. This must be done using aseptic technique by qualified personnel (often an unblinded pharmacist).

Dispense and Educate: Provide the IP to the subject. Crucially, the coordinator must educate the subject on how to take the IP, storage requirements at home, and the importance of returning all empty bottles, unused pills, and packaging at the next visit.

Update Logs: Document the dispensing on both the Master IP Accountability Log and the Subject-Specific IP Log.

IP Accountability Documentation

Accountability is the core of IP management. The FDA and sponsors require sites to account for every single pill, vial, or device from the moment it arrives until it is destroyed or returned.

The Master IP Accountability Log

This log tracks the overall inventory at the site level. It acts like a bank ledger for the IP.

Date Transaction Type Kit/Lot # Quantity Received Quantity Dispensed Quantity Returned Balance Forward Initials

  • 1-Oct Receipt Lot A 100 bottles 0 0 100 RC
  • 5-Oct Dispensed (Sub 01) Kit 45 0 1 bottle 0 99 RC
  • 12-Oct Dispensed (Sub 02) Kit 82 0 1 bottle 0 98 RC
  • The Subject-Specific IP Log

This log tracks the IP assigned to an individual subject. It details exactly what was given to the subject and what they brought back.

Date Dispensed Kit # Quantity Dispensed Date Returned Quantity Expected Back Quantity Actually Returned Discrepancy/Notes Initials

  • 5-Oct 45 30 pills 4-Nov 2 pills 2 pills 100% compliant RC
  • Managing Discrepancies

Discrepancies occur when the physical inventory does not match the written logs. If a subject returns fewer pills than expected, the coordinator must investigate.

Did the subject lose a pill?

Did they take an extra dose?

Did they drop one down the sink?

All discrepancies must be documented with a clear, signed, and dated explanation. Unexplained discrepancies are major red flags during an audit, as they suggest a breakdown in the site's control over the investigational product.